Cargando…
Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. However, patients are more satisfied with biologicals than with other treatments. The aim of our study was to assess patient pref...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461256/ https://www.ncbi.nlm.nih.gov/pubmed/26058083 http://dx.doi.org/10.1371/journal.pone.0129120 |
_version_ | 1782375504994631680 |
---|---|
author | Kromer, Christian Schaarschmidt, Marthe-Lisa Schmieder, Astrid Herr, Raphael Goerdt, Sergij Peitsch, Wiebke K. |
author_facet | Kromer, Christian Schaarschmidt, Marthe-Lisa Schmieder, Astrid Herr, Raphael Goerdt, Sergij Peitsch, Wiebke K. |
author_sort | Kromer, Christian |
collection | PubMed |
description | Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. However, patients are more satisfied with biologicals than with other treatments. The aim of our study was to assess patient preferences for treatment of psoriasis with biologicals by using computer-based conjoint analysis. Biologicals approved for psoriasis in Germany were decomposed into outcome (probability of 50% and 90% improvement, time until response, sustainability of success, probability of mild and severe adverse events (AE), probability of American College of Rheumatology (ACR) 20 response) and process attributes (treatment location, frequency, duration and delivery method). Impact of sociodemographic and socioeconomic characteristics and disease severity on Relative Importance Scores (RIS) of each attribute was assessed with analyses of variance, post hoc tests, and multivariate regression. Averaged across the cohort of 200 participants with moderate-to-severe psoriasis, preferences were highest for avoiding severe AE (RIS = 17.3), followed by 90% improvement (RIS = 14.0) and avoiding mild AE (RIS = 10.5). Process attributes reached intermediate RIS (8.2–8.8). Men were more concerned about efficacy than women (50% improvement: RIS = 6.9 vs. 9.5, p = 0.008; β = -0.191, p = 0.011 in multivariate models; 90% improvement: RIS = 12.1 vs. 15.4, p = 0.002; β = -0.197, p = 0.009). Older participants judged the probability of 50% and 90% improvement less relevant than younger ones (50% improvement: Pearson’s Correlation (PC) = -0.161, p = 0.022; β = -0.219, p = 0.017; 90% improvement: PC = -0.155, p = 0.028; β = -0.264, p = 0.004) but worried more about severe AE (PC = 0.175, p = 0.013; β = 0.166, p = 0.082). In summary, participants with moderate-to-severe psoriasis were most interested in safety of biologicals, followed by efficacy, but preferences varied with sociodemographic characteristics and working status. Based on this knowledge, physicians should identify preferences of each individual patient during shared decision-making in order to optimize treatment satisfaction, adherence and outcome. |
format | Online Article Text |
id | pubmed-4461256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44612562015-06-16 Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment Kromer, Christian Schaarschmidt, Marthe-Lisa Schmieder, Astrid Herr, Raphael Goerdt, Sergij Peitsch, Wiebke K. PLoS One Research Article Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. However, patients are more satisfied with biologicals than with other treatments. The aim of our study was to assess patient preferences for treatment of psoriasis with biologicals by using computer-based conjoint analysis. Biologicals approved for psoriasis in Germany were decomposed into outcome (probability of 50% and 90% improvement, time until response, sustainability of success, probability of mild and severe adverse events (AE), probability of American College of Rheumatology (ACR) 20 response) and process attributes (treatment location, frequency, duration and delivery method). Impact of sociodemographic and socioeconomic characteristics and disease severity on Relative Importance Scores (RIS) of each attribute was assessed with analyses of variance, post hoc tests, and multivariate regression. Averaged across the cohort of 200 participants with moderate-to-severe psoriasis, preferences were highest for avoiding severe AE (RIS = 17.3), followed by 90% improvement (RIS = 14.0) and avoiding mild AE (RIS = 10.5). Process attributes reached intermediate RIS (8.2–8.8). Men were more concerned about efficacy than women (50% improvement: RIS = 6.9 vs. 9.5, p = 0.008; β = -0.191, p = 0.011 in multivariate models; 90% improvement: RIS = 12.1 vs. 15.4, p = 0.002; β = -0.197, p = 0.009). Older participants judged the probability of 50% and 90% improvement less relevant than younger ones (50% improvement: Pearson’s Correlation (PC) = -0.161, p = 0.022; β = -0.219, p = 0.017; 90% improvement: PC = -0.155, p = 0.028; β = -0.264, p = 0.004) but worried more about severe AE (PC = 0.175, p = 0.013; β = 0.166, p = 0.082). In summary, participants with moderate-to-severe psoriasis were most interested in safety of biologicals, followed by efficacy, but preferences varied with sociodemographic characteristics and working status. Based on this knowledge, physicians should identify preferences of each individual patient during shared decision-making in order to optimize treatment satisfaction, adherence and outcome. Public Library of Science 2015-06-09 /pmc/articles/PMC4461256/ /pubmed/26058083 http://dx.doi.org/10.1371/journal.pone.0129120 Text en © 2015 Kromer et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kromer, Christian Schaarschmidt, Marthe-Lisa Schmieder, Astrid Herr, Raphael Goerdt, Sergij Peitsch, Wiebke K. Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
title | Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
title_full | Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
title_fullStr | Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
title_full_unstemmed | Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
title_short | Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
title_sort | patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461256/ https://www.ncbi.nlm.nih.gov/pubmed/26058083 http://dx.doi.org/10.1371/journal.pone.0129120 |
work_keys_str_mv | AT kromerchristian patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment AT schaarschmidtmarthelisa patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment AT schmiederastrid patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment AT herrraphael patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment AT goerdtsergij patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment AT peitschwiebkek patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment |